CRSP director Douglas A. Treco purchases 20,000 shares for $1.1M, 10x his prior 2,000-share position
Director Treco Douglas A purchased 20,000 shares at $57.03 on 2025-08-06, expanding his holdings from 2,000 to 22,000 shares—a 1000.0% increase in position size. This is a material acquisition by a board-level insider following substantial recent price momentum: the stock is at $55.00 today, down 19.3% from its 52-week high of $68.14 but up 54.4% over the past 90 days. The purchase occurred in the context of significant fundamental headwinds: CRISPR Therapeutics reported -90.0% annual revenue growth, negative full-year net income of $-208,549,000.00, and quarterly revenue of only $892,000.00, indicating the company is deeply unprofitable and contracting. A director's acquisition of this magnitude warrants investor scrutiny regarding his conviction in the near-term outlook, given the company's deteriorating financial trajectory and whether the 90-day rally presents information asymmetry into the market.